secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001213900-25-112383
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients
------------------------------------------------------------------------

- 8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.
- 80% (8/10) of patients that completed treatment achieved clinical success.
- 5/6 macrocystic patients had complete response; mixed cystic patient also complete response.
- No serious adverse events; common AEs were swelling and fatigue; one discontinuation due to Grade 2 fatigue.
- Two LMs patients reached 32-week post-treatment and remain disease-free.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/0001213900-25-112383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea0266384-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-112383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer